Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | J. Brahmer, M. Johnson, M. Awad, A. Rajan, A. Allred, R. Knoblauch, E. Zudaire, M. Lorenzi, R. Hassan | ||||||||||||
Title | P2.07-058 First-In-Human Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, for Non-Small Cell Lung Cancer | ||||||||||||
|
|||||||||||||
URL | https://www.jto.org/article/S1556-0864(17)32049-X/abstract | ||||||||||||
Abstract Text |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
JNJ-64041757 | JNJ-64041757 | 0 | 0 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-64041757 | ADU-214|JNJ-757|Pemlimogene merolisbac | JNJ-64041757 (pemlimogene merolisbac) is a immunotherapy based on live attenuated Listeria monocytogenes, which may enhance immune response against mesothelin-expressing tumor cells (J Thoracic Oncol, Vol 12, Issue 11, S2151). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|